ClinicalTrials.gg
RecruitingNCT06601335Updated Nov 14, 2024

A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

A Phase 3 interventional study of AK117 in combination with AK112 and Placebo in combination with Pembrolizumab in Head and Neck Squamous Cell Carcinoma, sponsored by Akeso. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China — 171 open to participants now, 205 under way, 25 of them phase 3. Squamous Cell Carcinoma of Head and Neck · China.

Planned enrollment
16th of 265
510 · median 68
Started
2024
with 40 others
Phase 3
32 of 290
21 open now
Primary completion
2027-01
later than 96 of 204 live
Registered
182nd of 290
by date

Among the 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, this one is the 16th largest by planned enrollment of the 265 interventional ones that give a count, is one of 41 that started in 2024, is one of 32 in phase 3, reaches primary completion later than 96 of the 204 other live ones, and was the 182nd registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

171 of the 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China are open now. Recruiting first, the newest first:

166 more — sign in →

All 171 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, or all of them as a file.
02

Study summary

This is a phase 3 study. All subjects arerecurrent or metastatic head and neck squamous Cell Carcinoma (R/M HNSCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with AK117 versus pembrolizumab combined with placebo in patients with R/M HNSCC whose tumors have programmed cell death-ligand 1 (PD-L1) positive [Combined Positive Score (CPS) greater than or equal to 1].

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able and willing to provide written .
  2. Have an (ECOG) performance status of 0 or 1.
  3. Have a of at least 3 months.
  4. Has confirmed diagnosis of R/M HNSCC primarily located in oropharynx, oral cavity, hypopharynx, or larynx, which is considered incurable by local therapies.
  5. Participants with oropharyngeal cancer must have results from testing of human papillomavirus HPV status.
  6. No prior systemic treatment for R/M HNSCC.
  7. At least one measurable noncerebral lesion according to 1.1.
  8. positive (CPS ≥ 1).
  9. Has adequate organ function.
  10. All subjects of must agree to use an effective method of , as determined by the Investigator, during and for 120 days after the last dose of study treatment.
  11. Able to to comply with all requirements of study participation (including all study procedures).

Exclusion criteria

Exclusion Criteria:

  1. Has squamous cell carcinoma of the primary site, such as nasopharynx, nasal cavity, sinuses, salivary glands, thyroid or parathyroid, skin, or of unknown primary origin.
  2. Had other malignant tumors within the 5 years prior to enrollment.
  3. Has a significant risk of bleeding assessed by the investigator based on imaging.
  4. Radiologically documented evidence of major blood vessel invasion or tumor invading organs or there is a risk of esophagotracheal or esophagopleural fistula, or major blood vessel encasement that the investigator determines will pose a significantly increased risk of bleeding.
  5. Has known active central nervous system (CNS) .
  6. Has pleural effusion, pericardial effusion, or ascites with clinical symptoms or requiring repeated drainage.
  7. Previously received immunotherapy, including , immune checkpoint agonists, immune cell therapy, and any other treatments targeting the immune mechanisms of tumors.
  8. Previously received radiation therapy for head or neck within 8 weeks prior to enrollment, received palliative radiation therapy for non-head or non-neck within 3 weeks prior to enrollment.
  9. Has a history severe bleeding tendency or coagulation dysfunction.
  10. Has a history myocarditis, cardiomyopathy, and malignant arrhythmia.
  11. Has a history arterial or venous thromboembolism events, , cerebrovascular accidents, hypertensive crises, or hypertensive encephalopathy occurred within 6 months prior to enrollment.
  12. Pregnant or lactating female.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
510 participants (estimated)

Study arms

  • Experimental
    AK117 in combination with AK112

    Drug: AK117 in combination with AK112

  • Active comparator
    Placebo in combination with Pembrolizumab

    Drug: Placebo in combination with Pembrolizumab

Interventions

  • DrugAK117 in combination with AK112

    Drug pages: Ligufalimab · Ivonescimab

    Following a predefined dose and date.

  • DrugPlacebo in combination with Pembrolizumab

    Following a predefined dose and date.

This study also gives Pembrolizumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is the time from randomization to death due to any cause.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization to the first documented disease progression (per RECIST v1.1 criteria) assessed by investigators or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  2. Objective Response Rate (ORR)

    ORR is the proportion of subjects with complete response(CR) or partial response(PR) , assessed by investigators based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  3. Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to approximately 2 years

  4. Cmax

    Maximum plasma concentration of AK112 and AK117 after administration.

    Time frame: Up to approximately 2 years

  5. Cmin

    Minimum plasma concentration of AK112 and AK117 after administration.

    Time frame: Up to approximately 2 years

  6. Anti-drug antibodies (ADA)

    Number of subjects with detectable ADA.

    Time frame: Up to approximately 2 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jan 2027, 27 months after the start.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2024
First posted
Sep 19, 2024
StartActual
Oct 30, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Oct 2027
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06601335
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 30, 2024
Primary completion
Jan 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 14, 2024

Study contacts

Wenting Li
Contact
wenting01.li@akesobio.com
18116403289

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ligufalimab · Ivonescimab

Start the discussion